DSpace Home
→
Browsing by Author

Browsing by Author "Unal Egeli"

Now showing items 1-13 of 13

An in vitro model for the development of acquired tamoxifen resistance

Güney Eskiler, Gamze; Gulsah Cecener; Berrin Tunca; Unal Egeli (SPRINGER, 2016)

The development of resistance to tamoxifen (Tam) remains a challenging clinical problem for ER+ breast cancer patients. To understand the mechanisms underlying of resistance, previous studies have driven the acquisition ...
BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile

Güney Eskiler, Gamze; Güney Eskiler, Gamze; Gulsah Cecener; Unal Egeli; Berrin Tunca (WILEY, 2019)

The objective of the present study was to elucidate the effect of BMN 673 (talozoparib) on BRCA1 mutant (HCC1937) and wild-type (MDA-MB-231) triple negative breast cancer (TNBC). The in vitro cytotoxicity results indicated ...
E-Health and Bioengineering Conference

Güney Eskiler, Gamze; Gulsah Cecener; Unal Egeli; Berrin Tunca (IEEE, 2017)

The anti-estrogen tamoxifen (Tam) is the most preferred option for patients with estrogen-receptor (ER)-positive breast cancer. However, multi-drug resistance (MDR) is a considerable clinical problem in the successful ...
E-Health and Bioengineering Conference

Isil Ezgi Eryilmaz; Güney Eskiler, Gamze; Gulsah Cecener; Unal Egeli; Berrin Tunca (IEEE, 2017)

We mentioned the importance of clinical sequence analysis in risk determination, diagnostic and therapeutic process of familial breast cancer and we also summarized next generation sequencing applications in this cancer ...
In vitro cytotoxic and antiproliferative effects of usnic acid on hormone-dependent breast and prostate cancer cells

Isil Ezgi Eryilmaz; Güney Eskiler, Gamze; Unal Egeli; Beste Yurdacan; Gulsah Cecener; Berrin Tunca (WILEY, 2018)

The aim of the current study was first to investigate cytotoxic activity of usnic acid (UA) on hormone-dependent breast and prostate cancer, and normal cells. Cells were treated with increasing concentrations (25 to 150 ...
Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid

Beste Yurdacan; Unal Egeli; Güney Eskiler, Gamze; Güney Eskiler, Gamze; Isil Ezgi Eryilmaz; Gulsah Cecener; Berrin Tunca (WILEY, 2019)

Objectives Sorafenib (SOR) is an orally administered molecular targeted agent in the systemic chemotherapy of hepatocellular carcinoma (HCC). However, the partial response of SOR is limited due to its adverse side effect ...
Potential role of solid lipid nanoparticles in overcoming the acquired tamoxifen resistance of breast cancer

Gulsah Cecener; Güney Eskiler, Gamze; Unal Egeli; Berrin Tunca (ELSEVIER SCIENCE BV, 2017)
Synergistic effects of hormone therapy drugs and usnic acid on hormone receptor-positive breast and prostate cancer cells

Güney Eskiler, Gamze; Güney Eskiler, Gamze; Isil Ezgi Eryilmaz; Beste Yurdacan; Unal Egeli; Gulsah Cecener; Berrin Tunca (WILEY, 2019)

The aim of this study was to investigate the combined effects of usnic acid (UA) and Tamoxifen (Tam) or Enzalutamide (Enz) on hormone receptor-positive breast and prostate cancer (BC and PC), respectively. The antiproliferative ...
Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer

Güney Eskiler, Gamze; Gulsah Cecener; Unal Egeli; Berrin Tunca (SPRINGER/PLENUM PUBLISHERS, 2018)

PurposeThe purpose of the study was to produce BMN 673 loaded solid lipid nanoparticles (SLNs) to improve its therapeutic index, to minimize toxicity and to overcome homologous recombination (HR)-mediated resistance.Meth ...
Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In Vitro

Güney Eskiler, Gamze; Güney Eskiler, Gamze; Gulsah Cecener; Gokhan Dikmen; Unal Egeli; Berrin Tunca (BENTHAM SCIENCE PUBL LTD, 2019)

Conclusion: The apoptotic rates in the 10 nM BMN 673-SLNs treatment (88.78% and 85.56%) for 12 days were significantly higher than those in 10 nM BMN 673 (82.6% and 25.86%) for 12 days in HCC1937 and HCC1937-R cells, ...
Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer

Güney Eskiler, Gamze; Gulsah Cecener; Unal Egeli; Berrin Tunca (WILEY, 2020)

Herein, we investigated efflux pumps-mediated talazoparib-resistance in the treatment of triple-negative breast cancer (TNBC). Furthermore, we produced a novel talazoparib-solid lipid nanoparticles (SLNs) and then explored ...
The Anticancer Activity of Complex [Cu-2(mu-(C6H5)(2)CHCOO)(3)(bipy)(2))](ClO4) -Solid Lipid Nanoparticles on MCF-7 Cells

Ibrahim Kani; Gokhan Dikmen; Güney Eskiler, Gamze; Güney Eskiler, Gamze; Gulsah Cecener; Berrin Tunca; Unal Egeli (BENTHAM SCIENCE PUBL LTD, 2016)

Recent studies have focused on the potential use of metal-based complexes for the treatment of cancer. However, there are some limitations of metal-based ligands for the treatment of cancer due to their toxic effects. In ...
Triple negative breast cancer: new therapeutic approaches and BRCA status

Güney Eskiler, Gamze; Gulsah Cecener; Unal Egeli; Berrin Tunca (WILEY, 2018)

Treatment of triple negative breast cancer (TNBC) is a clinically challenging problem due to intriguing clinical and pathologic features of TNBC and natural or induced resistance to existing therapies. However, a great ...